Resistance to therapy in acute promyelocytic leukemia.

Resistance to treatment in patients with acute promyelocytic leukemia is rare. The authors describe the development of resistance to arsenic through a mutation in the allele of PML that is not rearranged as the PML-RARA oncogenic driver.

[1]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[2]  Ya-Zhen Qin,et al.  Resistance to arsenic therapy in acute promyelocytic leukemia. , 2014, The New England journal of medicine.

[3]  B. George,et al.  Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Minucci,et al.  Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure , 2014, Nature Medicine.

[5]  Yuan-fang Liu,et al.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.